JP2012070739A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012070739A5 JP2012070739A5 JP2011235756A JP2011235756A JP2012070739A5 JP 2012070739 A5 JP2012070739 A5 JP 2012070739A5 JP 2011235756 A JP2011235756 A JP 2011235756A JP 2011235756 A JP2011235756 A JP 2011235756A JP 2012070739 A5 JP2012070739 A5 JP 2012070739A5
- Authority
- JP
- Japan
- Prior art keywords
- actriib polypeptide
- disease
- amino acid
- domain
- soluble
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59076504P | 2004-07-23 | 2004-07-23 | |
| US60/590,765 | 2004-07-23 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007522846A Division JP2008507288A (ja) | 2004-07-23 | 2005-07-25 | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014046188A Division JP2014138607A (ja) | 2004-07-23 | 2014-03-10 | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012070739A JP2012070739A (ja) | 2012-04-12 |
| JP2012070739A5 true JP2012070739A5 (https=) | 2013-01-17 |
Family
ID=34981761
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007522846A Withdrawn JP2008507288A (ja) | 2004-07-23 | 2005-07-25 | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
| JP2011235756A Withdrawn JP2012070739A (ja) | 2004-07-23 | 2011-10-27 | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
| JP2014046188A Withdrawn JP2014138607A (ja) | 2004-07-23 | 2014-03-10 | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
| JP2015243744A Withdrawn JP2016094449A (ja) | 2004-07-23 | 2015-12-15 | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
| JP2018006070A Withdrawn JP2018100275A (ja) | 2004-07-23 | 2018-01-18 | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
| JP2019193970A Pending JP2020015763A (ja) | 2004-07-23 | 2019-10-25 | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
| JP2020023608A Pending JP2020073604A (ja) | 2004-07-23 | 2020-02-14 | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007522846A Withdrawn JP2008507288A (ja) | 2004-07-23 | 2005-07-25 | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014046188A Withdrawn JP2014138607A (ja) | 2004-07-23 | 2014-03-10 | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
| JP2015243744A Withdrawn JP2016094449A (ja) | 2004-07-23 | 2015-12-15 | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
| JP2018006070A Withdrawn JP2018100275A (ja) | 2004-07-23 | 2018-01-18 | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
| JP2019193970A Pending JP2020015763A (ja) | 2004-07-23 | 2019-10-25 | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
| JP2020023608A Pending JP2020073604A (ja) | 2004-07-23 | 2020-02-14 | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US7709605B2 (https=) |
| EP (5) | EP1771470B1 (https=) |
| JP (7) | JP2008507288A (https=) |
| AU (1) | AU2005266875B2 (https=) |
| CA (2) | CA2574777C (https=) |
| DK (1) | DK2332977T3 (https=) |
| ES (4) | ES2426005T3 (https=) |
| PT (1) | PT1771470E (https=) |
| WO (1) | WO2006012627A2 (https=) |
Families Citing this family (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1771470B1 (en) * | 2004-07-23 | 2013-06-26 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
| EP1802326A2 (en) * | 2004-09-09 | 2007-07-04 | Stryker Corporation | Methods for treating bone tumors using bone morphogenic proteins |
| US7855279B2 (en) * | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| KR20190006086A (ko) * | 2005-11-23 | 2019-01-16 | 악셀레론 파마 인코포레이티드 | 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도 |
| AU2015201033B2 (en) * | 2005-11-23 | 2017-03-16 | Acceleron Pharma Inc. | Activin-ActRIIa antagonists and uses for promoting bone growth |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| KR20170012582A (ko) * | 2006-11-02 | 2017-02-02 | 악셀레론 파마 인코포레이티드 | Ａｌｋ１ 수용체 및 리간드 길항제 및 그의 용도 |
| DK2124999T3 (da) * | 2006-12-18 | 2013-01-14 | Acceleron Pharma Inc | Activin-actrii antagonister og anvendelser til behandling af anæmi |
| AU2016250354B2 (en) * | 2006-12-18 | 2019-01-17 | Acceleron Pharma Inc. | Activin-ActRII antagonists and uses for increasing red blood cell levels |
| US8895016B2 (en) * | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| AU2013221910B2 (en) * | 2006-12-18 | 2016-11-17 | Acceleron Pharma Inc. | Activin-ActRII antagonists and uses for increasing red blood cell levels |
| EP2111229B1 (en) | 2007-02-01 | 2013-04-10 | Acceleron Pharma, Inc. | Pharmaceutical compositions comprising Activin-ActRIIA antagonists for use in preventing or treating breast cancer metastasis or breast cancer related bone loss |
| TWI782836B (zh) * | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| ES2756725T3 (es) | 2007-02-09 | 2020-04-27 | Acceleron Pharma Inc | Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIA |
| US8501678B2 (en) | 2007-03-06 | 2013-08-06 | Atara Biotherapeutics, Inc. | Variant activin receptor polypeptides and uses thereof |
| TWI573802B (zh) | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
| US20090017019A1 (en) * | 2007-06-01 | 2009-01-15 | Wyeth | Methods and compositions for modulating bmp-10 activity |
| JP2010535708A (ja) | 2007-08-03 | 2010-11-25 | ビオマリン アイジーエー リミテッド | デュシェンヌ型筋ジストロフィーの治療のための薬物併用 |
| GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
| EP3243524A1 (en) * | 2007-09-18 | 2017-11-15 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
| WO2009137075A1 (en) * | 2008-05-06 | 2009-11-12 | Acceleron Pharma Inc. | Anti-activin antibodies and uses for promoting bone growth |
| AU2009262970A1 (en) * | 2008-06-26 | 2009-12-30 | Acceleron Pharma Inc. | Methods for dosing an activin-ActRIIa antagonist and monitoring of treated patients |
| JP5773868B2 (ja) | 2008-06-26 | 2015-09-02 | アクセルロン ファーマ， インコーポレイテッド | アクチビン−ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用 |
| SMT202300222T1 (it) * | 2008-08-14 | 2023-09-06 | Acceleron Pharma Inc | Trappole di gdf |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| SG10201703067QA (en) | 2008-11-26 | 2017-05-30 | Amgen Inc | Variants Of Activin IIB Receptor Polypeptides And Uses Thereof |
| US8138142B2 (en) | 2009-01-13 | 2012-03-20 | Acceleron Pharma Inc. | Methods for increasing adiponectin in a patient in need thereof |
| CA2748314C (en) | 2009-02-03 | 2018-10-02 | Amunix Operating Inc. | Extended recombinant polypeptides and compositions comprising same |
| JP5766179B2 (ja) | 2009-04-27 | 2015-08-19 | ノバルティス アーゲー | 筋肉増殖を増加させるための組成物および方法 |
| BRPI1010587A2 (pt) * | 2009-06-08 | 2019-04-09 | Acceleron Pharma Inc. | métodos para aumentar adipócitos termogênicos |
| US9849188B2 (en) | 2009-06-08 | 2017-12-26 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
| JP5839597B2 (ja) | 2009-06-08 | 2016-01-06 | アムニクス オペレーティング インコーポレイテッド | グルコース調節ポリペプチド並びにその作成及び使用方法 |
| EP2440577A4 (en) * | 2009-06-12 | 2013-01-23 | Acceleron Pharma Inc | SHORTEN ACTRIIB FC FUSION PROTEINS |
| KR20180085825A (ko) | 2009-08-13 | 2018-07-27 | 악셀레론 파마 인코포레이티드 | 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용 |
| BR112012005225B8 (pt) * | 2009-09-09 | 2023-01-10 | Acceleron Pharma Inc | Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente |
| WO2011056497A1 (en) * | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor type iib compositions and methods of use |
| EP3818988A1 (en) * | 2009-11-03 | 2021-05-12 | Acceleron Pharma Inc. | Methods for treating fatty liver disease |
| JP6267425B2 (ja) | 2009-11-17 | 2018-01-24 | アクセルロン ファーマ， インコーポレイテッド | 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用 |
| WO2011123830A2 (en) | 2010-04-02 | 2011-10-06 | Amunix Operating Inc. | Alpha 1-antitrypsin compositions and methods of making and using same |
| CN103298832A (zh) * | 2010-11-08 | 2013-09-11 | 阿塞勒隆制药公司 | Actriia结合剂及其用途 |
| BR112014009528B1 (pt) | 2011-10-17 | 2020-12-29 | Acceleron Pharma, Inc. | usos de polipeptídeos actriib para a fabricação de um medicamento para tratar eritropoiese ineficaz |
| GR1007832B (el) * | 2011-11-21 | 2013-02-14 | Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, | Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη" |
| HK1203384A1 (en) | 2011-12-19 | 2015-12-11 | Amgen Inc. | Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof |
| CN117462693A (zh) | 2012-02-27 | 2024-01-30 | 阿穆尼克斯运营公司 | Xten缀合组合物和制造其的方法 |
| US9809636B2 (en) | 2012-04-06 | 2017-11-07 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels comprising administering BMP9 |
| JP2015525230A (ja) | 2012-06-11 | 2015-09-03 | アムジエン・インコーポレーテツド | デュアル受容体アンタゴニスト性抗原結合タンパク質およびその使用 |
| ES3047691T3 (en) | 2012-08-01 | 2025-12-04 | Ikaika Therapeutics Inc | Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4) |
| SG11201501013PA (en) | 2012-08-10 | 2015-04-29 | Opx Biotechnologies Inc | Microorganisms and methods for the production of fatty acids and fatty acid derived products |
| CN104968801B (zh) | 2012-10-24 | 2021-06-15 | 细胞基因公司 | 用于治疗贫血症的生物标志物 |
| AU2013334660B2 (en) | 2012-10-24 | 2018-08-09 | Celgene Corporation | Methods for treating anemia |
| NZ707477A (en) | 2012-11-02 | 2019-09-27 | Celgene Corp | Activin-actrii antagonists and uses for treating bone and other disorders |
| SG10201706148WA (en) | 2013-02-01 | 2017-08-30 | Santa Maria Biotherapeutics Inc | Administration of an anti-activin-a compound to a subject |
| EP2983694B1 (en) | 2013-04-08 | 2022-06-22 | President and Fellows of Harvard College | Compositions for rejuvenating skeletal muscle stem cells |
| US11408013B2 (en) | 2013-07-19 | 2022-08-09 | Cargill, Incorporated | Microorganisms and methods for the production of fatty acids and fatty acid derived products |
| DK3037524T3 (da) | 2013-08-23 | 2020-03-16 | Sumitomo Chemical Co | Fremgangsmåde til at fremstille nethindevæv og nethinderelaterede celler |
| EP3094751A4 (en) * | 2014-01-14 | 2017-06-07 | Santa Maria Biotherapeutics, Inc. | Activin inhibitor response prediction and uses for treatment |
| US20170248609A1 (en) | 2014-01-27 | 2017-08-31 | Novartis Ag | Biomarkers predictive of muscle atrophy, method and use |
| WO2015152183A1 (ja) * | 2014-03-31 | 2015-10-08 | 大日本住友製薬株式会社 | 進行性骨化性線維異形成症の予防剤及び治療剤 |
| MX388380B (es) | 2014-04-18 | 2025-03-19 | Acceleron Pharma Inc | Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes. |
| US10023621B2 (en) * | 2014-06-04 | 2018-07-17 | Acceleron Pharma Inc. | Follistatin-related fusion proteins |
| US10010498B2 (en) | 2014-06-04 | 2018-07-03 | Acceleron Pharma Inc. | Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins |
| WO2015192111A1 (en) | 2014-06-13 | 2015-12-17 | Acceleron Pharma, Inc. | Methods and compositions for treating ulcers |
| EP2993228B1 (en) | 2014-09-02 | 2019-10-09 | Cargill, Incorporated | Production of fatty acid esters |
| US20160075772A1 (en) | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
| MA41052A (fr) * | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| JP2018501307A (ja) | 2014-12-03 | 2018-01-18 | セルジーン コーポレイション | アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用 |
| EP3256148A1 (en) | 2015-02-12 | 2017-12-20 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease |
| AU2016238254B2 (en) | 2015-03-26 | 2022-05-05 | Acceleron Pharma Inc. | Follistatin-related fusion proteins and uses thereof |
| CN107849114B (zh) | 2015-04-06 | 2021-08-20 | 阿塞勒隆制药公司 | 单臂i型和ii型受体融合蛋白和其用途 |
| MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| US10227392B2 (en) | 2015-04-06 | 2019-03-12 | Acceleron Pharma Inc. | ALK7:ActRIIB heteromultimers and uses thereof |
| PT3286206T (pt) | 2015-04-22 | 2021-04-01 | Biogen Ma Inc | Novas proteínas híbridas bloqueadoras de ligando actriib para tratar doenças de desgaste muscular |
| MA42160A (fr) | 2015-05-20 | 2018-03-28 | Maria Cappellini | Procédés de culture de cellules in vitro pour la beta-thalassemie a l'aide de pieges a ligands du recepteur de l'activine de type ii |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| US11123430B2 (en) | 2015-11-04 | 2021-09-21 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| CA3005975A1 (en) | 2015-11-23 | 2017-06-01 | Acceleron Pharma Inc. | Methods for treating eye disorders |
| CA3010799A1 (en) | 2016-01-06 | 2017-07-13 | President And Fellows Of Harvard College | Treatment with gdf11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis |
| JP6987072B2 (ja) | 2016-03-10 | 2021-12-22 | アクセレロン ファーマ インコーポレーテッド | アクチビン２型受容体結合タンパク質及びその使用 |
| WO2017177013A1 (en) | 2016-04-06 | 2017-10-12 | Acceleron Pharma Inc. | Alk7 antagonists and uses thereof |
| HRP20210694T1 (hr) | 2016-07-15 | 2021-09-17 | Acceleron Pharma, Inc. | Pripravci koji sadrže actriia polipeptide za uporabu za liječenje plućne hipertenzije |
| PL3490582T3 (pl) | 2016-07-27 | 2024-09-23 | Acceleron Pharma Inc. | Kompozycje do zastosowania w leczeniu mielofibrozy |
| BR112019006993A2 (pt) | 2016-10-05 | 2019-09-03 | Acceleron Pharma Inc | heteromultímeros de alk4:actriib e usos dos mesmos |
| JP2019529509A (ja) | 2016-10-05 | 2019-10-17 | アクセレロン ファーマ インコーポレーテッド | 腎臓疾患を治療するための組成物および方法 |
| JP7280182B2 (ja) | 2016-10-05 | 2023-05-23 | アクセルロン ファーマ インコーポレイテッド | バリアントＡｃｔＲＩＩＢタンパク質およびその使用 |
| JOP20190085A1 (ar) * | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| CN110430890B (zh) * | 2016-11-10 | 2024-09-10 | 科乐斯疗法公司 | 激活素受体iia型变体及其使用方法 |
| EP3577227A4 (en) | 2017-02-02 | 2020-12-30 | Cargill Inc. | GENETICALLY MODIFIED CELLS PRODUCING C6-C10 FATTY ACID DERIVATIVES |
| FI3600415T3 (fi) | 2017-03-24 | 2025-12-05 | Novartis Ag | Aktiviinireseptorin tyypin ii reseptorin vastainen vasta-aine käytettäväksi sydämen vajaatoiminnan hoidossa |
| HRP20241477T1 (hr) | 2017-06-14 | 2025-01-03 | Celgene Corporation | Postupci liječenja mijeloproliferativne neoplazme povezane s mijelofibrozom i anemijom |
| CN107267637B (zh) * | 2017-07-25 | 2021-08-24 | 华南农业大学 | 一种鸡肌间脂肪宽度相关的分子标记及其应用 |
| EP3706777B1 (en) * | 2017-11-09 | 2024-05-22 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| IL320014A (en) | 2018-01-12 | 2025-06-01 | Keros Therapeutics Inc | Activin receptor type iib variants and methods of use thereof |
| JP7405772B2 (ja) * | 2018-05-09 | 2023-12-26 | ケロス セラピューティクス インコーポレイテッド | アクチビンｉｉａ型受容体変異体および同変異体を含む医薬組成物 |
| CA3124415A1 (en) | 2018-12-21 | 2020-06-25 | Northwestern University | Use of annexins in preventing and treating muscle membrane injury |
| US20220062299A1 (en) | 2018-12-26 | 2022-03-03 | Northwestern University | Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder |
| JP7663559B2 (ja) | 2019-09-03 | 2025-04-16 | ノバルティス アーゲー | Ａｃｔｒｉｉ受容体拮抗薬を含む肝疾患または肝臓障害の治療 |
| CN114761013A (zh) | 2019-09-27 | 2022-07-15 | 迪斯克医药公司 | 治疗骨髓纤维化和相关病症的方法 |
| WO2021142191A1 (en) | 2020-01-08 | 2021-07-15 | Regeneron Pharmaceuticals, Inc. | Treatment of fibrodysplasia ossificans progressiva |
| WO2021189010A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| IL296394A (en) | 2020-03-20 | 2022-11-01 | Keros Therapeutics Inc | Type ii activin receptor chimeras and methods of using them |
| WO2021189006A1 (en) * | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iia variants |
| EP4142769A4 (en) | 2020-04-28 | 2024-05-15 | Acceleron Pharma Inc. | ACTRII PROTEINS AND USE IN THE TREATMENT OF POSTCAPILLARY PULMONARY HYPERTENSION |
| WO2021231798A1 (en) | 2020-05-13 | 2021-11-18 | Disc Medicine, Inc. | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| CA3177632A1 (en) | 2020-05-15 | 2021-11-18 | Melih ACAR | Methods and compositions for treating anemia using actriib ligand traps and mtor inhibitors |
| WO2022072882A1 (en) * | 2020-10-02 | 2022-04-07 | Keros Therapeutics, Inc. | Methods of using activin receptor type ii variants |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
| KR102680764B1 (ko) * | 2021-08-03 | 2024-07-04 | 주식회사 와이뮨 | Acvr2b를 표적으로 하는 퇴행성 관절염 치료 또는 진단용 조성물 |
| US20250041385A1 (en) | 2021-12-10 | 2025-02-06 | Biogen Ma Inc. | Modified actrii proteins and methods of use thereof |
| KR20240150761A (ko) | 2022-01-28 | 2024-10-16 | 35파마 인크. | 액티빈 수용체 유형 iib 변이체 및 이의 용도 |
| US20250002588A1 (en) | 2023-04-07 | 2025-01-02 | Diagonal Therapeutics Inc. | Bispecific agonistic antibodies to activin a receptor like type 1 (alk1) |
| US20260092096A1 (en) | 2024-05-14 | 2026-04-02 | 35Pharma Inc. | Activin receptor type iib variants and uses thereof |
| WO2026080757A2 (en) | 2024-10-09 | 2026-04-16 | Diagonal Therapeutics Inc. | Activin receptor type ii a/b (actriia/b) antibodies |
Family Cites Families (158)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3382562D1 (de) | 1982-09-24 | 1992-06-25 | Us Health | Wiederherstellung von gewebe bei tieren. |
| NZ210699A (en) | 1984-01-04 | 1989-06-28 | Int Genetic Eng | Isolation of an osteogenic protein of the p3 immunologically related family |
| DE3588058T3 (de) | 1984-07-16 | 2005-04-07 | Celtrix Pharmaceuticals, Inc., Palo Alto | Knorpel-induzierende Polypeptid-Faktoren aus Knochen |
| JPH0637520B2 (ja) * | 1985-07-03 | 1994-05-18 | 味の素株式会社 | ポリペプチド |
| AU597574B2 (en) | 1986-03-07 | 1990-06-07 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
| US4973577A (en) * | 1986-04-04 | 1990-11-27 | The Salk Institute For Biological Studies | FSH-releasing peptides |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| EP0548276A4 (en) | 1990-09-13 | 1993-12-29 | Children's Hospital Medical Center Of Northern California | Method for increasing red blood cell production by treatment with activin or activin-related peptides |
| US5118667A (en) * | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
| US6162896A (en) * | 1991-05-10 | 2000-12-19 | The Salk Institute For Biological Studies | Recombinant vertebrate activin receptors |
| JPH06500574A (ja) * | 1991-05-10 | 1994-01-20 | ザ ソーク インスティテュート フォア バイオロジカル スタディーズ | アクチビン／ＴＧＦ―βスーパーファミリーのレセプターのクローニングおよび組換えによる産生 |
| US5885794A (en) * | 1991-05-10 | 1999-03-23 | The Salk Institute For Biological Studies | Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily |
| US20050186593A1 (en) | 1991-05-10 | 2005-08-25 | The Salk Institute For Biological Studies | Cloning and recombinant production of CRF receptor(s) |
| US6287816B1 (en) | 1991-06-25 | 2001-09-11 | Genetics Institute, Inc. | BMP-9 compositions |
| AU652472B2 (en) | 1991-06-25 | 1994-08-25 | Genetics Institute, Llc | BMP-9 compositions |
| US6692925B1 (en) * | 1992-11-17 | 2004-02-17 | Ludwig Institute For Cancer Research | Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use |
| WO1994015965A1 (en) | 1993-01-12 | 1994-07-21 | Johns Hopkins University School Of Medicine | Growth differentiation factor-3 |
| EP0698095B1 (en) | 1993-05-12 | 2004-04-28 | Genetics Institute, LLC | Bmp-10 compositions |
| US5637480A (en) | 1993-05-12 | 1997-06-10 | Genetics Institute, Inc. | DNA molecules encoding bone morphogenetic protein-10 |
| US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
| US5831050A (en) * | 1993-06-07 | 1998-11-03 | Creative Biomolecules, Inc. | Morphogen cell surface receptor |
| DE69434934D1 (de) | 1993-10-14 | 2007-04-12 | Harvard College | Verfahren zur induzierung und zur erhaltung neuronalen zellen |
| US5525490A (en) | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
| US5658876A (en) | 1994-04-28 | 1997-08-19 | The General Hospital Corporation | Activin antagonists as novel contraceptives |
| US5760010A (en) | 1995-01-01 | 1998-06-02 | Klein; Ira | Method of treating liver disorders with a macrolide antibiotic |
| US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
| DE69636866D1 (en) | 1995-04-11 | 2007-03-15 | Gen Hospital Corp | Reverse "two-hybrid"-systeme |
| JPH1072497A (ja) * | 1995-10-27 | 1998-03-17 | Takeda Chem Ind Ltd | 神経系細胞特異的レセプター蛋白質 |
| EP0771873A3 (en) * | 1995-10-27 | 1998-03-04 | Takeda Chemical Industries, Ltd. | Neuronal cell-specific receptor protein |
| GB9526131D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Recombinant chimeric receptors |
| US6004780A (en) * | 1996-03-26 | 1999-12-21 | Human Genome Sciences, Inc. | Growth factor HTTER36 |
| US20050244867A1 (en) * | 1996-03-26 | 2005-11-03 | Human Genome Sciences, Inc. | Growth factor HTTER36 |
| US6605699B1 (en) * | 1997-01-21 | 2003-08-12 | Human Genome Sciences, Inc. | Galectin-11 polypeptides |
| AU7478298A (en) * | 1997-05-16 | 1998-12-08 | Procter & Gamble Company, The | The use of a bone morphogenetic protein (bmp) receptor complex for screening |
| US6231880B1 (en) * | 1997-05-30 | 2001-05-15 | Susan P. Perrine | Compositions and administration of compositions for the treatment of blood disorders |
| ATE417927T1 (de) | 1997-07-30 | 2009-01-15 | Univ Emory | Neue knochenmineralisierungsproteine, dna, vektoren, expressionssysteme |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| US6696260B1 (en) * | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
| AU8666398A (en) | 1997-08-01 | 1999-02-22 | Johns Hopkins University School Of Medicine, The | Methods to identify growth differentiation factor (gdf) receptors |
| US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US6372454B2 (en) * | 1997-08-29 | 2002-04-16 | Human Genome Sciences, Inc. | Nucleic acid molecules encoding Follistatin-3 |
| US6953662B2 (en) * | 1997-08-29 | 2005-10-11 | Human Genome Sciences, Inc. | Follistatin-3 |
| AU738192B2 (en) * | 1997-09-19 | 2001-09-13 | Neuren Pharmaceuticals Limited | Neuronal rescue agent |
| US6696411B1 (en) * | 1998-04-22 | 2004-02-24 | Cornell Research Foundation, Inc. | Canine erythropoietin gene and recombinant protein |
| CN1317967A (zh) | 1998-09-17 | 2001-10-17 | 伊莱利利公司 | 蛋白质制剂 |
| AU5502799A (en) * | 1998-09-22 | 2000-04-10 | Long Yu | New human growth differentiation factor encoding sequence and polypeptide encoded by such dna sequence and producing method thereof |
| US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| US6548634B1 (en) | 1998-09-30 | 2003-04-15 | Chiron Corporation | Synthetic peptides having FGF receptor affinity |
| US6777205B1 (en) * | 1998-11-06 | 2004-08-17 | Sterrenbeld Biotechnologie North America, Inc. | Host cells expressing recombinant human erythropoietin |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| AU772694B2 (en) | 1999-01-21 | 2004-05-06 | Metamorphix International, Inc. | Growth differentiation factor inhibitors and uses therefor |
| EP1174149A1 (en) | 1999-04-19 | 2002-01-23 | Kyowa Hakko Kogyo Co., Ltd. | Proliferation inhibitor for androgen-independent tumor |
| US6468543B1 (en) * | 1999-05-03 | 2002-10-22 | Zymogenetics, Inc. | Methods for promoting growth of bone using ZVEGF4 |
| US7358056B1 (en) * | 1999-08-30 | 2008-04-15 | Signal Pharmaceuticals | Methods for modulating signal transduction mediated by TGF-β and related proteins |
| SK8292002A3 (en) | 1999-11-12 | 2002-12-03 | Maxygen Holdings Ltd | A conjugate exhibiting interferon gamma activity, nucleotide sequence encoding for a polypeptide fraction of conjugate, an expression vector and a host cell containing nucleotide sequence, pharmaceutical composition comprising the same and use thereof |
| AU777166B2 (en) | 1999-12-15 | 2004-10-07 | Research Development Foundation | Betaglycan as an inhibin receptor and uses thereof |
| JP4487376B2 (ja) * | 2000-03-31 | 2010-06-23 | 味の素株式会社 | 腎疾患治療剤 |
| US6627424B1 (en) * | 2000-05-26 | 2003-09-30 | Mj Bioworks, Inc. | Nucleic acid modifying enzymes |
| US6632180B1 (en) | 2000-09-07 | 2003-10-14 | John H. Laragh | Method for evaluating and treating hypertension |
| DE10045591A1 (de) | 2000-09-15 | 2002-04-04 | Klaus Pfizenmaier | Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine) |
| US7087224B2 (en) * | 2000-10-31 | 2006-08-08 | Amgen Inc. | Method of treating anemia by administering IL-1ra |
| DK1345959T3 (da) * | 2000-11-20 | 2011-09-05 | Univ Illinois | Membranscaffoldproteiner |
| AU2002236558A1 (en) | 2000-12-01 | 2002-06-11 | Regents Of The University Of California | Method and composition for modulating bone growth |
| TWI329129B (en) * | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
| US20040132675A1 (en) * | 2002-02-08 | 2004-07-08 | Calvin Kuo | Method for treating cancer and increasing hematocrit levels |
| WO2002074340A1 (fr) | 2001-03-16 | 2002-09-26 | Takeda Chemical Industries, Ltd. | Procede de fabrication d'une preparation a liberation continue |
| BRPI0209933B8 (pt) | 2001-05-24 | 2021-05-25 | Zymogenetics Inc | proteína de fusão, e, molécula de ácido nucleico |
| EP1390497A2 (en) * | 2001-05-25 | 2004-02-25 | Genset | Human cdnas and proteins and uses thereof |
| AUPR638101A0 (en) * | 2001-07-13 | 2001-08-09 | Bioa Pty Limited | Composition and method for treatment of disease |
| US7396642B2 (en) | 2001-07-17 | 2008-07-08 | Teijin Limited | Methods of screening for a compound that enhances thermogenesis |
| US6855344B2 (en) * | 2001-07-17 | 2005-02-15 | Integrated Chinese Medicine Holdings, Ltd. | Compositions and methods for prostate and kidney health and disorders, an herbal preparation |
| KR100453877B1 (ko) | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
| US7320789B2 (en) * | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| US6784154B2 (en) * | 2001-11-01 | 2004-08-31 | University Of Utah Research Foundation | Method of use of erythropoietin to treat ischemic acute renal failure |
| US20030144203A1 (en) | 2001-12-19 | 2003-07-31 | Voyager Pharmaceutical Corporation | Methods for slowing senescence and treating and preventing diseases associated with senescence |
| US6998118B2 (en) * | 2001-12-21 | 2006-02-14 | The Salk Institute For Biological Studies | Targeted retrograde gene delivery for neuronal protection |
| CA2476887A1 (en) * | 2002-02-21 | 2003-09-04 | Wyeth | Gasp1:a follistatin domain containing protein |
| US20030219846A1 (en) | 2002-02-28 | 2003-11-27 | Pfizer Inc. | Assay for activity of the ActRIIB kinase |
| AU2003232485A1 (en) | 2002-04-18 | 2003-10-27 | Mtm Laboratories Ag | Neopeptides and methods useful for detection and treatment of cancer |
| KR20050083635A (ko) | 2002-08-16 | 2005-08-26 | 와이어쓰 | Ｂｍｐ-2 에스트로겐 반응 요소 및 이의 사용 방법 |
| AR047392A1 (es) * | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
| US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| AU2002953327A0 (en) | 2002-12-12 | 2003-01-09 | Monash University | Methods of diagnosing prognosing and treating activin associated diseases and conditions |
| DK1592416T3 (da) | 2003-02-07 | 2009-04-20 | Prometic Biosciences Inc | Fedtsyrer med middel kædelængde, glycerider og analoger som stimulatorer af erythropoiesis |
| US20040197828A1 (en) * | 2003-03-26 | 2004-10-07 | Gaddy Dana P. | Method for diagnosis and treatment of bone turnover |
| WO2005028517A2 (en) | 2003-05-09 | 2005-03-31 | The General Hospital Corporation | SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS |
| BRPI0410927A (pt) | 2003-06-02 | 2006-06-27 | Wyeth Corp | métodos terapêuticos e profiláticos para distúrbios neuromusculares |
| EP1636270B1 (en) | 2003-06-16 | 2016-07-20 | UCB Pharma S.A. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
| WO2005009460A2 (en) | 2003-07-25 | 2005-02-03 | Medexis, S.A. | Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer |
| US8895540B2 (en) | 2003-11-26 | 2014-11-25 | DePuy Synthes Products, LLC | Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor |
| PL1706428T3 (pl) | 2004-01-22 | 2010-02-26 | Merck Patent Gmbh | Przeciwciała przeciwnowotworowe o zredukowanym wiązaniu dopełniacza |
| US20050197292A1 (en) * | 2004-01-30 | 2005-09-08 | Glennda Smithson | Compositions and methods for treating T-cell mediated pathological conditions |
| EP1732589A2 (en) | 2004-03-26 | 2006-12-20 | Acceleron Pharma Inc. | Bmp-3 propeptides and related methods |
| US7459527B2 (en) | 2004-03-31 | 2008-12-02 | Xencor, Inc. | BMP-7 variants with improved properties |
| US7741284B2 (en) | 2004-05-12 | 2010-06-22 | Acceleron Pharma Inc. | BMP10 propeptides and related methods |
| US7465706B2 (en) | 2004-06-24 | 2008-12-16 | Acceleron Pharma Inc. | GDF3 propeptides and related methods |
| EP1771470B1 (en) * | 2004-07-23 | 2013-06-26 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
| AU2005272646A1 (en) | 2004-08-12 | 2006-02-23 | Wyeth | Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors |
| WO2006039400A2 (en) | 2004-09-29 | 2006-04-13 | Mount Sinai School Of Medicine Of New York University | Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis |
| NZ538097A (en) | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
| US7968091B2 (en) | 2005-02-16 | 2011-06-28 | The General Hospital Corporation | Methods and compositions to regulate iron metabolism |
| JPWO2006115274A1 (ja) | 2005-04-26 | 2008-12-18 | 味の素株式会社 | 骨髄赤血球前駆細胞分化促進剤 |
| JP2007099764A (ja) | 2005-09-09 | 2007-04-19 | Ajinomoto Co Inc | 血糖低下剤 |
| EA015351B1 (ru) | 2005-09-28 | 2011-06-30 | Займодженетикс, Инк. | Антагонисты il-17a и il-17f и способы их применения |
| US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| KR20190006086A (ko) | 2005-11-23 | 2019-01-16 | 악셀레론 파마 인코포레이티드 | 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도 |
| JP2009518422A (ja) | 2005-12-06 | 2009-05-07 | アムジェン インコーポレイテッド | ミオスタチン・アンタゴニストの使用 |
| EP1966183A4 (en) | 2005-12-20 | 2010-12-29 | Merck Frosst Canada Ltd | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A-DELTA-9-DESATURASE |
| MX2008008340A (es) | 2005-12-21 | 2008-09-03 | Schering Corp | Tratamiento de enfermedad de higado graso no alcoholica usando agentes reductores de colesterol y/o antagonista/agonista inverso de receptor de histamina 3. |
| EP1973909A2 (en) | 2005-12-22 | 2008-10-01 | Biogen Idec MA Inc. | Transforming growth factor modulators |
| JP4925364B2 (ja) * | 2006-01-20 | 2012-04-25 | ベックマン コールター， インコーポレイテッド | 鉄欠乏を検出する方法 |
| EP1976377A4 (en) | 2006-01-25 | 2010-06-23 | Wellstat Therapeutics Corp | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS |
| US20100227901A1 (en) | 2006-02-28 | 2010-09-09 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| US20080102065A1 (en) * | 2006-04-14 | 2008-05-01 | Borges Luis G | Erythropoietin receptor extended duration limited agonists |
| CN101489544A (zh) * | 2006-05-09 | 2009-07-22 | 海玛奎斯特医药公司 | 治疗血液病的方法 |
| PL2048948T3 (pl) * | 2006-07-21 | 2012-07-31 | Lyne Laboratories Inc | Płynne kompozycje octanu wapnia |
| GB0615129D0 (en) | 2006-07-29 | 2006-09-06 | Univ Cardiff | Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies |
| CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| US7547781B2 (en) * | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| WO2008060139A1 (en) | 2006-11-17 | 2008-05-22 | Erasmus University Medical Center Rotterdam | Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein |
| WO2008073292A2 (en) | 2006-12-08 | 2008-06-19 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Method for protecting renal tubular epithelial cells from radiocontrast nephro parhy (rcn) |
| JP5632582B2 (ja) | 2006-12-14 | 2014-11-26 | 中外製薬株式会社 | 抗Ｃｌａｕｄｉｎ３モノクローナル抗体およびそれを用いる癌の治療および診断 |
| DK2124999T3 (da) * | 2006-12-18 | 2013-01-14 | Acceleron Pharma Inc | Activin-actrii antagonister og anvendelser til behandling af anæmi |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| US20100028332A1 (en) | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| EP2111229B1 (en) * | 2007-02-01 | 2013-04-10 | Acceleron Pharma, Inc. | Pharmaceutical compositions comprising Activin-ActRIIA antagonists for use in preventing or treating breast cancer metastasis or breast cancer related bone loss |
| TWI782836B (zh) * | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| ES2756725T3 (es) * | 2007-02-09 | 2020-04-27 | Acceleron Pharma Inc | Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIA |
| TWI573802B (zh) | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
| US20090017019A1 (en) * | 2007-06-01 | 2009-01-15 | Wyeth | Methods and compositions for modulating bmp-10 activity |
| WO2009009059A1 (en) | 2007-07-09 | 2009-01-15 | Biogen Idec Ma Inc. | Spiro compounds as antagonists of tgf-beta |
| JP2010535708A (ja) | 2007-08-03 | 2010-11-25 | ビオマリン アイジーエー リミテッド | デュシェンヌ型筋ジストロフィーの治療のための薬物併用 |
| GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
| GB0715938D0 (en) | 2007-08-15 | 2007-09-26 | Vastox Plc | Method of treatment of duchenne muscular dystrophy |
| WO2009025651A1 (en) | 2007-08-17 | 2009-02-26 | University Of Maine System Board Of Trustees | Biologically active peptide and method of using the same |
| EP3243524A1 (en) | 2007-09-18 | 2017-11-15 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
| PE20091163A1 (es) * | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| CN101925611A (zh) | 2007-11-21 | 2010-12-22 | 安姆根有限公司 | Wise结合剂和表位 |
| CN102083969A (zh) | 2008-05-06 | 2011-06-01 | 乔斯林糖尿病中心股份有限公司 | 诱导褐色脂肪形成的方法和组合物 |
| WO2009137075A1 (en) | 2008-05-06 | 2009-11-12 | Acceleron Pharma Inc. | Anti-activin antibodies and uses for promoting bone growth |
| AU2009262970A1 (en) | 2008-06-26 | 2009-12-30 | Acceleron Pharma Inc. | Methods for dosing an activin-ActRIIa antagonist and monitoring of treated patients |
| JP5773868B2 (ja) | 2008-06-26 | 2015-09-02 | アクセルロン ファーマ， インコーポレイテッド | アクチビン−ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用 |
| SMT202300222T1 (it) * | 2008-08-14 | 2023-09-06 | Acceleron Pharma Inc | Trappole di gdf |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| US8138142B2 (en) * | 2009-01-13 | 2012-03-20 | Acceleron Pharma Inc. | Methods for increasing adiponectin in a patient in need thereof |
| JP5766179B2 (ja) | 2009-04-27 | 2015-08-19 | ノバルティス アーゲー | 筋肉増殖を増加させるための組成物および方法 |
| BRPI1010587A2 (pt) | 2009-06-08 | 2019-04-09 | Acceleron Pharma Inc. | métodos para aumentar adipócitos termogênicos |
| EP2440577A4 (en) | 2009-06-12 | 2013-01-23 | Acceleron Pharma Inc | SHORTEN ACTRIIB FC FUSION PROTEINS |
| KR20180085825A (ko) | 2009-08-13 | 2018-07-27 | 악셀레론 파마 인코포레이티드 | 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용 |
| BR112012005225B8 (pt) | 2009-09-09 | 2023-01-10 | Acceleron Pharma Inc | Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente |
| EP3818988A1 (en) | 2009-11-03 | 2021-05-12 | Acceleron Pharma Inc. | Methods for treating fatty liver disease |
| JP6267425B2 (ja) | 2009-11-17 | 2018-01-24 | アクセルロン ファーマ， インコーポレイテッド | 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用 |
| BR112014009528B1 (pt) | 2011-10-17 | 2020-12-29 | Acceleron Pharma, Inc. | usos de polipeptídeos actriib para a fabricação de um medicamento para tratar eritropoiese ineficaz |
| CN104411720B (zh) | 2012-07-02 | 2018-05-11 | 协和发酵麒麟株式会社 | 以抗bmp9抗体作为有效成分的、对肾性贫血、癌性贫血等贫血的治疗剂 |
-
2005
- 2005-07-25 EP EP05775451.7A patent/EP1771470B1/en not_active Expired - Lifetime
- 2005-07-25 PT PT57754517T patent/PT1771470E/pt unknown
- 2005-07-25 AU AU2005266875A patent/AU2005266875B2/en not_active Expired
- 2005-07-25 ES ES05775451T patent/ES2426005T3/es not_active Expired - Lifetime
- 2005-07-25 WO PCT/US2005/026368 patent/WO2006012627A2/en not_active Ceased
- 2005-07-25 ES ES10009258.4T patent/ES2561048T3/es not_active Expired - Lifetime
- 2005-07-25 US US11/190,202 patent/US7709605B2/en active Active
- 2005-07-25 EP EP15196071.3A patent/EP3059245B1/en not_active Expired - Lifetime
- 2005-07-25 EP EP10009236.0A patent/EP2314617B1/en not_active Expired - Lifetime
- 2005-07-25 EP EP10009258.4A patent/EP2332977B1/en not_active Expired - Lifetime
- 2005-07-25 JP JP2007522846A patent/JP2008507288A/ja not_active Withdrawn
- 2005-07-25 EP EP18197548.3A patent/EP3489257A1/en not_active Withdrawn
- 2005-07-25 ES ES10009236.0T patent/ES2551852T3/es not_active Expired - Lifetime
- 2005-07-25 DK DK10009258.4T patent/DK2332977T3/en active
- 2005-07-25 CA CA2574777A patent/CA2574777C/en not_active Expired - Lifetime
- 2005-07-25 ES ES15196071T patent/ES2710048T3/es not_active Expired - Lifetime
- 2005-07-25 CA CA2891010A patent/CA2891010C/en not_active Expired - Lifetime
-
2010
- 2010-03-31 US US12/751,868 patent/US8252900B2/en not_active Expired - Lifetime
-
2011
- 2011-10-27 JP JP2011235756A patent/JP2012070739A/ja not_active Withdrawn
-
2012
- 2012-08-17 US US13/588,468 patent/US9138459B2/en not_active Expired - Lifetime
-
2014
- 2014-03-10 JP JP2014046188A patent/JP2014138607A/ja not_active Withdrawn
-
2015
- 2015-08-26 US US14/836,684 patent/US20160108379A1/en not_active Abandoned
- 2015-12-15 JP JP2015243744A patent/JP2016094449A/ja not_active Withdrawn
-
2018
- 2018-01-18 JP JP2018006070A patent/JP2018100275A/ja not_active Withdrawn
- 2018-12-17 US US16/222,562 patent/US20190352619A1/en not_active Abandoned
-
2019
- 2019-10-25 JP JP2019193970A patent/JP2020015763A/ja active Pending
-
2020
- 2020-02-14 JP JP2020023608A patent/JP2020073604A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012070739A5 (https=) | ||
| RU2017138537A (ru) | Новые гибридные ActRIIB белки-ловушки лигандов для лечения заболеваний, связанных с мышечной атрофией | |
| JP2018512873A5 (https=) | ||
| JP6542433B2 (ja) | 単独でのまたは化学療法と組み合わされた変異アクチビン受容体ポリペプチド、およびその使用 | |
| JP2019535675A5 (https=) | ||
| TW201827069A (zh) | 用於治療肌肉萎縮和骨疾病的新型雜合actriib配體陷阱蛋白 | |
| He et al. | Collagen and collagen mimetic peptide conjugates in polymer science | |
| JP2020063249A (ja) | 修飾された治療剤、及びその組成物 | |
| JP2012509687A5 (https=) | ||
| JP2010519931A5 (https=) | ||
| JP2019059738A (ja) | Ｇｄｆ−８に対する改善された拮抗抗体およびその使用 | |
| JP2011526792A5 (https=) | ||
| JP2012525844A5 (https=) | ||
| JP2019503167A5 (https=) | ||
| JP2012514126A5 (https=) | ||
| JP2016513669A5 (https=) | ||
| JP2017533194A5 (https=) | ||
| JP2009511579A5 (https=) | ||
| JP2013027391A5 (https=) | ||
| JP2013526864A5 (https=) | ||
| JP2013532644A5 (https=) | ||
| JP2014525735A5 (https=) | ||
| CN107645955A (zh) | 修饰的治疗剂及其组合物 | |
| JP2014510519A5 (https=) | ||
| JP2017538712A5 (https=) |